Strides Pharma Science Ltd
STAR
Company Profile
Business description
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.
Contact
Strides House, Bannerghatta Road
Bilekahalli
BengaluruKA560 076
INDT: +91 8067840000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
2,364
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,570.90 | 30.80 | -0.36% |
| CAC 40 | 8,154.51 | 31.93 | 0.39% |
| DAX 40 | 22,287.56 | 27.09 | -0.12% |
| Dow JONES (US) | 43,493.51 | 683.14 | -1.55% |
| FTSE 100 | 8,659.37 | 3.60 | -0.04% |
| HKSE | 23,477.92 | 900.94 | 3.99% |
| NASDAQ | 19,644.06 | 318.30 | -1.59% |
| Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
| NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
| S&P 500 | 6,036.09 | 81.43 | -1.33% |
| S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
| SSE Composite Index | 3,379.11 | 28.33 | 0.85% |